Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion

Studies showed that endothelin-1 (ET-1) was increased in the acute myocardial infarction (AMI). Experimental studies reported that captopril was able to reduce ET-1 secretion, and that ET-1 was increased during reperfusion. This study was aimed to verify if captopril was able to reduce plasma ET-1 during thrombolysis in AMI. Seventy-three patients, hospitalized for suspected AMI within 4 h from the onset of symptoms suitable for thrombolysis (1st episode), Killip class 1–2, were randomized (double blind) into two groups: group 1 (37 pts), 8 F/29 M, received captopril, 6.25 mg, orally 15 min before thrombolysis. Group 2: (36 pts) 8 F/28 M, received placebo before thrombolysis. All patients met the reperfusion criteria. Plasma ET-1 were checked on admission, at 1 h and at 2 h, after starting thrombolysis. Group 1 contained ten unstable angina, 17 anterior and ten inferior AMIs. Group 2 contained ten unstable angina, 16 anterior and ten inferior AMIs. Mean concentrations of ET-1: Unstable angina: group 1, basal — 4.56, at 1 h — 4.47, 2 h — 5.89 pg/ml; group 2: basal — 4.17, at 1 h — 4.59, 2 h — 5.24 pg/ml. Inferior AMI: group 1: basal — 6.87, 1 h — 7.75, 2 h — 8.47; group 2: basal — 6.34, 1 h — 6.68, 2 h — 7.98 pg/ml. Anterior AMI: group 1: basal — 7.17, 1 h — 7.93, 2 h — 10.76 pg/ml (between basal and 2-h samples P < 0.05); group 2: basal — 7.46, 1 h — 7.51, 2 h — 10.74 pg/ml. Differences between the two groups were not significant. Our data suggest that captopril does not affect plasma ET-1 during thrombolysis.